AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26045549 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed start protocol (Gn then Cetrotide 0.25 mg sc added when leading follicle reaches >12 mm)
Number of subjects: 160
Study 26045549 — intervention group
Group type: COMPARATOR
Intervention: Conventional GnRH antagonist protocol (Cetrotide 0.25 mg sc from day 2 to day 8, then Gn therapy added)
Number of subjects: 160
Study 24453922 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace noise exposure
Number of subjects: 555
Study 21606537 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC-3TC
Number of subjects: 269
Study 21606537 — intervention group
Group type: COMPARATOR
Intervention: TDF-FTC
Number of subjects: 269
Study 21606537 — intervention group
Group type: EXPERIMENTAL
Intervention: EFV
Number of subjects: 269
Study 21606537 — intervention group
Group type: COMPARATOR
Intervention: ATV/r
Number of subjects: 269
Study 21606537 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 269
Study 19117121 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g etofenamate (group 1)
Number of subjects: 70
Study 19117121 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (group 2)
Number of subjects: 70
Study 19117121 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (group 1 and group 2)
Number of subjects: 70
Study 16076380 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer hydrochloride 2250 mg/day
Number of subjects: 65
Study 16076380 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer hydrochloride 3000 mg/day
Number of subjects: 65
Study 12240756 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 30
Study 10072008 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal sufentanil 7.5 microg + bupivacaine 2.5 mg + clonidine 50 microg
Number of subjects: 30
Study 10072008 — intervention group
Group type: COMPARATOR
Intervention: Spinal sufentanil 7.5 microg + bupivacaine 2.5 mg
Number of subjects: 30
Study 7575051 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg nicotine polacrilex
Number of subjects: 90
Study 7575051 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg nicotine polacrilex
Number of subjects: 90
Study 7575051 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.5 mg nicotine polacrilex)
Number of subjects: 90
Study 2318962 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal inoculation of antigen-antibody complexes
Number of subjects: 0
Study 2318962 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 7189144 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean proteins and pectins (EMD 35327)
Number of subjects: 20
Study 7189144 — intervention group
Group type: COMPARATOR
Intervention: Conventional 1000 kcal mixed diet
Number of subjects: 20
Study 30471383 — intervention group
Group type: EXPERIMENTAL
Intervention: Competitive learning environment (paired learning)
Number of subjects: 16
Study 30471383 — intervention group
Group type: COMPARATOR
Intervention: Non-competitive learning environment (alone)
Number of subjects: 16
Study 30471383 — intervention group
Group type: EXPERIMENTAL
Intervention: Both competitive and non-competitive learning environments
Number of subjects: 16
Study 27603790 — intervention group
Group type: EXPERIMENTAL
Intervention: Egregious security breach
Number of subjects: 76
Study 27603790 — intervention group
Group type: EXPERIMENTAL
Intervention: Station topic
Number of subjects: 76
Study 27603790 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 76
Study 25986643 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention among occupational physicians to enhance the initiation of work modifications
Number of subjects: 0
Study 23729801 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab 0.3 mg
Number of subjects: 35
Study 23729801 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab 3 mg
Number of subjects: 35
Study 23729801 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab 30 mg
Number of subjects: 35
Study 23729801 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab 60 mg
Number of subjects: 35
Study 23729801 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab 100 mg
Number of subjects: 35
Study 23729801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 21727276 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 1195
Study 21727276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1195
Study 19398651 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐00489791 10 mg
Number of subjects: 133
Study 19398651 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐00489791 20/40 mg
Number of subjects: 133
Study 19398651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 16731075 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-absorbing polyglactin 910
Number of subjects: 192
Study 16731075 — intervention group
Group type: COMPARATOR
Intervention: Chromic catgut
Number of subjects: 192
Study 16731075 — intervention group
Group type: COMPARATOR
Intervention: Standard polyglactin 910
Number of subjects: 192
Study 15885525 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated dual disorders treatments
Number of subjects: 152
Study 12094756 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportional hazards models with random effects
Number of subjects: 0
Study 12094756 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequentist approach - penalized maximum likelihood method
Number of subjects: 0
Study 12094756 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian approach - Gibbs sampling method
Number of subjects: 0
Study 10088066 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (up to 75 mg/day)
Number of subjects: 250
Study 10088066 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (up to 200 mg/day)
Number of subjects: 250
Study 10088066 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril + Metoprolol
Number of subjects: 250
Study 10088066 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 250
Study 10088066 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 250
Study 7769900 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemented formula with fish oil (DHA)
Number of subjects: 0
Study 7769900 — intervention group
Group type: COMPARATOR
Intervention: Placebo formula
Number of subjects: 0
Study 7769900 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfed infants
Number of subjects: 0
Study 2138051 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 2.5 mg/day
Number of subjects: 24
Study 2138051 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril (1.25 mg/day and 5.0 mg/day)
Number of subjects: 24
Study 2138051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 6772293 — intervention group
Group type: EXPERIMENTAL
Intervention: VAC plus adriamycin (Regimen I)
Number of subjects: 193
Study 6772293 — intervention group
Group type: COMPARATOR
Intervention: VAC alone (Regimen II)
Number of subjects: 193
Study 6772293 — intervention group
Group type: COMPARATOR
Intervention: VAC and bilateral pulmonary irradiation (Regimen III)
Number of subjects: 193
Study 6772293 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral pulmonary irradiation for subclinical disease
Number of subjects: 193
Study 6772293 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin added to VAC chemotherapy
Number of subjects: 193
Study 30522875 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant 20/15 mg
Number of subjects: 1824
Study 30522875 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant 40/30 mg
Number of subjects: 1824
Study 30522875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1824
Study 30522875 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant
Number of subjects: 1824
Study 29202801 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for anxiety and depression and providing appropriate care
Number of subjects: 0
Study 29202801 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening for anxiety and depression)
Number of subjects: 0
Study 26866766 — intervention group
Group type: EXPERIMENTAL
Intervention: Team games (high physical exertion and high cognitive engagement)
Number of subjects: 181
Study 26866766 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (high physical exertion but low cognitive engagement)
Number of subjects: 181
Study 26866766 — intervention group
Group type: COMPARATOR
Intervention: Control condition (low physical exertion and low cognitive engagement)
Number of subjects: 181
Study 21519879 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty syndrome
Number of subjects: 2581
Study 21519879 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty syndrome in demented patients
Number of subjects: 2581
Study 21519879 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty syndrome in nondemented older subjects
Number of subjects: 2581
Study 19444237 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified human milk
Number of subjects: 32
Study 19444237 — intervention group
Group type: COMPARATOR
Intervention: Assumed nutrient intakes
Number of subjects: 32
Study 19444237 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy intake
Number of subjects: 32
Study 17328806 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine plus artesunate (4 mg/kg/day x 3 d)
Number of subjects: 85
Study 17328806 — intervention group
Group type: COMPARATOR
Intervention: Amodiaquine plus placebo (10 mg/kg/day x 3 d)
Number of subjects: 85
Study 17328806 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine plus artesunate
Number of subjects: 85
Study 17328806 — intervention group
Group type: COMPARATOR
Intervention: Amodiaquine plus placebo
Number of subjects: 85
Study 15465986 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine plus interpersonal psychotherapy
Number of subjects: 114
Study 15465986 — intervention group
Group type: COMPARATOR
Intervention: Imipramine alone
Number of subjects: 114
Study 15465986 — intervention group
Group type: COMPARATOR
Intervention: Interpersonal psychotherapy alone
Number of subjects: 114
Study 15465986 — intervention group
Group type: COMPARATOR
Intervention: No active treatment (placebo)
Number of subjects: 114
Study 11145479 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin treatment (100 U/kg BW during 24 hours)
Number of subjects: 28
Study 11145479 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 28
Study 9876448 — intervention group
Group type: EXPERIMENTAL
Intervention: Endolymphatic irradiation with lipoiodine containing 131I (specific activity 4-6 mCu/ml)
Number of subjects: 2
Study 7989902 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion (10 ng kg‐1 min‐1) for 1 hour in EH
Number of subjects: 23
Study 7989902 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion during sodium nitroprusside (NP) infusion in EH
Number of subjects: 23
Study 2596543 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6-log unit neutral density filter
Number of subjects: 5
Study 2596543 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5-log unit neutral density filter on Humphrey perimeter
Number of subjects: 5
Study 2596543 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0-log unit neutral density filter on Octopus perimeter
Number of subjects: 5
Study 30280670 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron Bisglycinate Chelate (FeBC)
Number of subjects: 0
Study 30280670 — intervention group
Group type: COMPARATOR
Intervention: Polymaltose Iron (FeP)
Number of subjects: 0
Study 26922214 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite materials (Biphasic calcium sulphate [BCS] with β Tri‐Calcium Phosphate (β‐TCP) and Hydroxyapatite [HA])
Number of subjects: 36
Study 26922214 — intervention group
Group type: COMPARATOR
Intervention: Control group (natural healing)
Number of subjects: 36
Study 25399543 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium conditional incentive ($50/six months)
Number of subjects: 267
Study 25399543 — intervention group
Group type: EXPERIMENTAL
Intervention: High conditional incentive ($75/six months)
Number of subjects: 267
Study 25399543 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconditional incentive ($50/six months)
Number of subjects: 267
Study 25399543 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 267
Study 22585469 — intervention group
Group type: EXPERIMENTAL
Intervention: Levitan FPS Scope™ (LFS)
Number of subjects: 94
Study 22585469 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 94
Study 19497623 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 0
Study 19497623 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine XR
Number of subjects: 0
Study 19497623 — intervention group
Group type: COMPARATOR
Intervention: SSRIs
Number of subjects: 0
Study 19497623 — intervention group
Group type: COMPARATOR
Intervention: Mirtazapine
Number of subjects: 0
Study 17563401 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 1404
Study 17563401 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1404
Study 16274919 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults walking over obstacles
Number of subjects: 30
Study 16274919 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased obstacle height
Number of subjects: 30
Study 16274919 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy elderly adults negotiating obstacles
Number of subjects: 30
Study 12421067 — intervention group
Group type: EXPERIMENTAL
Intervention: More frequent syllabic primes
Number of subjects: 0
Study 12421067 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonword syllabic primes
Number of subjects: 0
Study 12421067 — intervention group
Group type: EXPERIMENTAL
Intervention: Monosyllabic pairs
Number of subjects: 0
Study 12421067 — intervention group
Group type: EXPERIMENTAL
Intervention: Syllables as primes
Number of subjects: 0
Study 9933789 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound contrast agents
Number of subjects: 0
Study 9933789 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted analysis of Doppler signals
Number of subjects: 0
Study 9933789 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced Doppler ultrasound
Number of subjects: 0
Study 7729640 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 90
Study 7729640 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 90
Study 7729640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 2188772 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril hydrochloride, 5, 10, 20, or 40 mg, once daily for 28 days
Number of subjects: 0
Study 2188772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6771173 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/day of epimestrol
Number of subjects: 20
Study 6771173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6771173 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 30888581 — intervention group
Group type: EXPERIMENTAL
Intervention: Cast metal onlay
Number of subjects: 30
Study 30888581 — intervention group
Group type: COMPARATOR
Intervention: Indirect resin onlay
Number of subjects: 30
Study 30560679 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (6 mg tablet)
Number of subjects: 15
Study 30560679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 27942207 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic walking training (12 weeks, three times a week)
Number of subjects: 45
Study 27942207 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 25256368 — intervention group
Group type: EXPERIMENTAL
Intervention: Encouraged group (n = 28)
Number of subjects: 55
Study 25256368 — intervention group
Group type: COMPARATOR
Intervention: Discouraged group (n = 27)
Number of subjects: 55
Study 22422743 — intervention group
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate
Number of subjects: 2
Study 22422743 — intervention group
Group type: COMPARATOR
Intervention: warfarin
Number of subjects: 2
Study 20060516 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 0
Study 20060516 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA)
Number of subjects: 0
Study 18025625 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5-microg remifentanil
Number of subjects: 60
Study 18025625 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil and different doses of remifentanil
Number of subjects: 60
Study 16060911 — intervention group
Group type: EXPERIMENTAL
Intervention: SOM230 250 microg
Number of subjects: 12
Study 16060911 — intervention group
Group type: EXPERIMENTAL
Intervention: SOM230 100 microg
Number of subjects: 12
Study 16060911 — intervention group
Group type: COMPARATOR
Intervention: OCT 100 microg
Number of subjects: 12
Study 14607681 — intervention group
Group type: EXPERIMENTAL
Intervention: High concentration glucose intravenously during 24 hours before operation
Number of subjects: 17
Study 14607681 — intervention group
Group type: COMPARATOR
Intervention: Control group (no glucose treatment)
Number of subjects: 17
Study 10949727 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin therapy
Number of subjects: 30
Study 10949727 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched)
Number of subjects: 30
Study 8932889 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 0
Study 8932889 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 1431014 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0
Study 1431014 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline or Lorazepam
Number of subjects: 0
Study 1431014 — intervention group
Group type: COMPARATOR
Intervention: Dothiepin
Number of subjects: 0
Study 3160273 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticholinergic treatment with ipratropium bromide (Atrovent)
Number of subjects: 6
Study 3160273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31257642 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM) with remote monitoring
Number of subjects: 0
Study 31257642 — intervention group
Group type: COMPARATOR
Intervention: Standard insulin therapy without CGM
Number of subjects: 0
Study 29166140 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 76
Study 29166140 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept 2 mg
Number of subjects: 76
Study 26494833 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat (FG-4592)
Number of subjects: 60
Study 26494833 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat with oral iron
Number of subjects: 60
Study 26494833 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat with IV iron
Number of subjects: 60
Study 26494833 — intervention group
Group type: COMPARATOR
Intervention: No iron
Number of subjects: 60
Study 26494833 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat
Number of subjects: 60
Study 24346757 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg once daily for 11 days
Number of subjects: 43
Study 24346757 — intervention group
Group type: COMPARATOR
Intervention: Duloxetine 60 mg once daily
Number of subjects: 43
Study 24346757 — intervention group
Group type: COMPARATOR
Intervention: Duloxetine
Number of subjects: 43
Study 24346757 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram 20 mg/d
Number of subjects: 43
Study 24160674 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging intervention to collect daily alcohol consumption data
Number of subjects: 82
Study 24160674 — intervention group
Group type: EXPERIMENTAL
Intervention: Text delivered intervention on monthly alcohol expenditure
Number of subjects: 82
Study 24160674 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging for surveillance and intervention
Number of subjects: 82
Study 20631210 — intervention group
Group type: EXPERIMENTAL
Intervention: Top‐down selective attention to the affective properties of taste stimuli
Number of subjects: 0
Study 20631210 — intervention group
Group type: EXPERIMENTAL
Intervention: Top‐down selective attention to the intensity of taste stimuli
Number of subjects: 0
Study 20631210 — intervention group
Group type: COMPARATOR
Intervention: Attention to pleasantness
Number of subjects: 0
Study 20631210 — intervention group
Group type: COMPARATOR
Intervention: Attention to intensity
Number of subjects: 0
Study 18167173 — intervention group
Group type: EXPERIMENTAL
Intervention: cis-9, trans-11-conjugated linoleic acid (CLA) 2 g/d for 12 weeks
Number of subjects: 40
Study 18167173 — intervention group
Group type: COMPARATOR
Intervention: Placebo (high-oleic acid sunflower-seed oil)
Number of subjects: 40
Study 16415704 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (10-20 mg/d)
Number of subjects: 304
Study 16415704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study 16415704 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (for nonrelapsing patients)
Number of subjects: 304
Study 16415704 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for nonrelapsing patients)
Number of subjects: 304
Study 16415704 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (for nonexacerbating nonrelapsing patients)
Number of subjects: 304
Study 12784163 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly athletes with LV hypertrophy
Number of subjects: 48
Study 12784163 — intervention group
Group type: COMPARATOR
Intervention: Hypertensive patients with LV hypertrophy
Number of subjects: 48
Study 12784163 — intervention group
Group type: COMPARATOR
Intervention: Healthy sedentary controls
Number of subjects: 48
Study 10982347 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN induction (daily) therapy
Number of subjects: 20
Study 10982347 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN plus ribavirin combination therapy
Number of subjects: 20